On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical ...

Cisgender gay and bisexual men, transgender women, and transgender men remain at higher risk for HIV acquisition.

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Doctors and front-line workers are watching closely as HIV rates increase significantly in Alberta.An annual Alberta Health ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

The executive director of the organization says gender inequality is one of the most important drivers of new infections, ...

Indigenous communities in Latin America say they are being excluded from the global HIV/AIDS response, leaving them without ...

The South African National Aids Council is meant to play a co-ordinating role in the country’s response to HIV, bringing ...

Kidney transplant between donors and recipients with HIV is successful, research shows, which may help addresses the organ ...